샘플 요청 목록

 카트 문의
시장보고서
상품코드
1790233

세계의 HSV 검사 시장 규모, 점유율, 동향 분석 : 유형별, 검사 유형별, 샘플 유형별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

HSV Testing Market Size, Share & Trends Analysis By Type, By Test Type, By Sample Type, By End-use, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

HSV 검사 시장 개요

세계 HSV 검사 시장 규모는 2024년에 6억 1,197만 달러로 추정되며 2025-2033년 5.96%의 연평균 복합 성장률(CAGR)로 성장하여 2033년에는 10억 1,775만 달러에 달할 것으로 예측됩니다. 이 시장에는 헤르페스 바이러스 1형과 2형의 적시적이고 신뢰할 수 있는 검출을 목표로 하는 진단 솔루션이 포함됩니다.

이 부문의 검사 플랫폼은 전통적인 혈청학적 방법부터 첨단 분자 분석에 이르기까지 다양하며, 다양한 헬스케어 환경에서 임상적 판단을 지원합니다. 이러한 솔루션은 주로 성병 관리 및 산전 검진에 활용되고 있으며, 분산형과 포인트 오브 케어(Point of Care)에서의 채택이 확대되고 있습니다. 헤르페스 바이러스 감염증의 발병률 증가와 더불어 국민들의 인식이 높아지고, 성 건강 검진에 대한 인식이 개선되면서 시장 확대에 힘을 보태고 있습니다. HSV 검사와 디지털 플랫폼 및 원격 진단 도구의 통합은 특히 자원이 부족하고 의료 혜택이 부족한 환경에서 의료 접근성을 더욱 확대하여 조기 발견과 적시 임상 개입을 가능하게 합니다.

분자진단 기술의 지속적인 발전으로 HSV 검사의 민감도와 소요시간이 개선되고 있습니다. 다른 성병 병원체와 함께 HSV를 검출할 수 있는 멀티플렉스 PCR 플랫폼은 특히 외래환자 및 응급의료 현장에서 임상적으로 선호되고 있습니다. 또한, 검체에서 검사 결과까지의 워크플로우를 개선한 새로운 검사 키트의 규제 당국 승인은 1차 진료 및 응급 의료 현장에서의 사용을 지원하고 있습니다.

STI 감시 및 예방 프로그램에 대한 정부의 이니셔티브와 자금 지원 증가도 시장 성장에 기여하고 있습니다. 공중보건 캠페인, 특히 청소년 및 생식건강을 대상으로 한 캠페인은 쉽고 정확한 HSV 검사에 대한 수요를 촉진하고 있습니다. 공중 보건 기관과 민간 진단 제공업체와의 개발 협력은 보다 광범위한 검사 접근을 가능하게 하여 선진국과 자원이 부족한 지역의 진단 격차를 줄이는 데 도움이 되고 있습니다.

목차

제1장 HSV 검사 시장 : 조사 방법과 범위

제2장 HSV 검사 시장 : 주요 요약

  • 시장 현황
  • 유형과 테스트 유형 현황
  • 샘플 유형 현황
  • 최종 용도 현황
  • 경쟁 구도 현황

제3장 HSV 검사 시장 변수, 동향 및 범위

  • 시장 세분화와 범위
  • 시장 계통 전망
    • 상위 시장 전망
    • 관련/보조 시장 전망
  • 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • Porter의 Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석

제4장 HSV 검사 시장 : 유형별, 추정 및 동향 분석

  • HSV 검사 시장 : 유형 변동 분석
  • HSV-1/HSV-2 혼합
  • HSV-1
  • HSV-2

제5장 HSV 검사 시장 : 검사 유형별, 추정 및 동향 분석

  • HSV 검사 시장 : 검사 유형 변동 분석
  • 혈청학적 검사
  • 직접 감지 검사
    • PCR
    • 바이러스 배양
  • POC(Point of Care) 검사

제6장 HSV 검사 시장 : 샘플 유형별, 추정 및 동향 분석

  • HSV 검사 시장 : 샘플 유형 변동 분석
  • 혈액
  • 면봉
  • 뇌척수액

제7장 HSV 검사 시장 : 최종 용도별, 추정 및 동향 분석

  • HSV 검사 시장 : 최종 용도 변동 분석
  • 병원
  • 진단실험실
  • 클리닉 및 성건강센터
  • 재택치료 및 셀프테스트

제8장 HSV 검사 시장 : 지역 비즈니스 분석

  • 지역 시장 스냅숏
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제9장 경쟁 구도

  • 기업 분류
  • 전략 매핑
    • 신제품 발매
    • 파트너십
    • 취득
    • 협업
    • 자금조달
  • 주요 기업의 시장 점유율 분석(2024년)
  • 기업 히트맵 분석
  • 기업 개요
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Thermo Fisher Scientific Inc.
    • BD
    • Bio-Rad Laboratories, Inc.
    • BIOMERIEUX
    • DiaSorin SpA
    • Hologic, Inc.
    • Cepheid
    • QuidelOrtho Corporation
LSH 25.08.20

HSV Testing Market Summary

The global HSV testing market size was estimated at USD 611.97 million in 2024 and is expected to reach USD 1017.75 million by 2033, growing at a CAGR of 5.96% from 2025 to 2033. This market encompasses diagnostic solutions aimed at the timely and reliable detection of herpes simplex virus types 1 and 2.

Testing platforms in this space range from traditional serological methods to advanced molecular assays, supporting clinical decisions across diverse healthcare environments. These solutions are primarily utilized in managing sexually transmitted infections and prenatal screening, with growing adoption in decentralized and point-of-care settings. The rising incidence of herpes simplex virus infections, along with heightened public awareness and efforts to improve sexual health screening, is supporting market expansion. Integration of HSV testing with digital platforms and remote diagnostic tools is further expanding access to care, particularly in low-resource and underserved settings, enabling earlier detection and timely clinical intervention.

Ongoing advancements in molecular diagnostic technologies are enhancing the sensitivity and turnaround time of HSV testing. Multiplex PCR platforms capable of detecting HSV alongside other sexually transmitted pathogens are gaining clinical preference, particularly in outpatient and emergency care settings. In addition, regulatory approvals for newer test kits with improved sample-to-answer workflows support their use in primary and urgent care environments.

Increased government initiatives and funding for STI surveillance and prevention programs also contribute to market growth. Public health campaigns, especially those targeting adolescent and reproductive health, are driving demand for accessible and accurate HSV testing. Collaborations between public health agencies and private diagnostic providers enable broader test availability, helping reduce diagnostic gaps in developed and resource-limited regions.

Global HSV Testing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global HSV testing market based on type, test type, sample type, end-use, and region:

  • Type Outlook (USD Million, 2021 - 2033)
  • HSV-1/HSV-2 Combines
  • HSV-1
  • HSV-2
  • Test Type Outlook (USD Million, 2021 - 2033)
  • Serological tests
  • Direct detection tests
    • PCR
    • Viral culture
  • Point-of-care tests
  • Sample Type Outlook (USD Million, 2021 - 2033)
  • Blood
  • Swabs
  • Cerebrospinal fluid
  • End-use Outlook (USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Clinics and Sexual Health Centers
  • Home care / Self-testing
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. HSV Testing Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Test Type Segment
      • 1.1.1.3. Sample Type segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. HSV Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Test Type Snapshot
  • 2.3. Sample Type Snapshot
  • 2.4. End Use Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. HSV Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising prevalence of HSV infections worldwide
    • 3.4.2. Advancements in molecular and point-of-care Testing technologies
    • 3.4.3. Public health initiatives and routine STI screening programs
  • 3.5. Market Restraint Analysis
    • 3.5.1. Limited diagnostic accuracy of serological tests
    • 3.5.2. Stigma and underreporting associated with HSV infections
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. HSV Testing Market: Type Estimates & Trend Analysis

  • 4.1. HSV Testing Market: Type Movement Analysis
  • 4.2. HSV-1/HSV-2 Combines
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. HSV-1
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. HSV-2
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. HSV Testing Market: Test Type Estimates & Trend Analysis

  • 5.1. HSV Testing Market: Test Type Movement Analysis
  • 5.2. Serological tests
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Direct detection tests
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.2. PCR
      • 5.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.3. Viral culture
      • 5.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Point-of-care tests
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. HSV Testing Market: Sample Type Estimates & Trend Analysis

  • 6.1. HSV Testing Market: Sample Type Movement Analysis
  • 6.2. Blood
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Swabs
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Cerebrospinal fluid
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. HSV Testing Market: End Use Estimates & Trend Analysis

  • 7.1. HSV Testing Market: End Use Movement Analysis
  • 7.2. Hospitals
    • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Diagnostic Laboratories
    • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Clinics and sexual health centers
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Home care / self-testing
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. HSV Testing Market: Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America HSV Testing Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Scenario
      • 8.2.2.5. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Scenario
      • 8.2.3.5. Competitive Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Scenario
      • 8.2.4.5. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe HSV Testing Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Scenario
      • 8.3.2.5. Competitive Scenario
    • 8.3.3. Germany
      • 8.3.3.1. Germany HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Scenario
      • 8.3.3.5. Competitive Scenario
    • 8.3.4. Spain
      • 8.3.4.1. Spain HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Scenario
      • 8.3.4.5. Competitive Scenario
    • 8.3.5. France
      • 8.3.5.1. France HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Scenario
      • 8.3.5.5. Competitive Scenario
    • 8.3.6. Italy
      • 8.3.6.1. Italy HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Scenario
      • 8.3.6.5. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Scenario
      • 8.3.7.5. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Scenario
      • 8.3.8.5. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Scenario
      • 8.3.9.5. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia-Pacific HSV Testing Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Scenario
      • 8.4.5.5. Competitive Scenario
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Scenario
      • 8.4.6.5. Competitive Scenario
    • 8.4.7. Australia
      • 8.4.7.1. Australia HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Scenario
      • 8.4.7.5. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America HSV Testing Market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.5.2.2. Key Country Dynamics
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. Competitive Scenario
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.5.3.2. Key Country Dynamics
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA HSV Testing Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait HSV Testing Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. NEW PRODUCT LAUNCH
    • 9.2.2. PARTNERSHIPS
    • 9.2.3. ACQUISITION
    • 9.2.4. COLLABORATION
    • 9.2.5. FUNDING
  • 9.3. Key Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. F. Hoffmann-La Roche Ltd.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Abbott
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Thermo Fisher Scientific Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. BD
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Bio-Rad Laboratories, Inc.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. BIOMERIEUX
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. DiaSorin S.p.A.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Hologic, Inc.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Cepheid
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. QuidelOrtho Corporation
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제